Magnesium lithospermate B improves the gut microbiome and bile acid metabolic profiles in a mouse model of diabetic nephropathy

Posted by: | July 2, 2018 | Comments

ABSTRACT

Magnesium lithospermate B improves the gut microbiome and bile acid metabolic profiles in a mouse model of diabetic nephropathy

Magnesium lithospermate B (MLB) is a new drug marketed in China to treat angina, but its low oral bioavailability limits its clinical application to the intravenous route. Paradoxically, orally administered low-dose MLB was found to alleviate kidney injury in diabetic nephropathy (DN) rats, but its mechanism of action remains unknown. In recent years, the kidney-gut axis has been suspected to be involved in kidney damage pathogenesis, potentially representing a non-classical pathway for pharmacologic intervention. To ascertain whether MLB targets the kidney-gut axis, streptozotocin (STZ)-treated mice were prepared as a mouse model of DN.

Read more at: Nature

Jing Zhao, et al. Acta Pharmacologica Sinica. https://doi.org/10.1038/s41401-018-0029-3. 25 June 2018.





Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy




Terms & Conditions | Privacy Policy | © 2018 The Translational Microbiome Research Forum